$1.1 Billion Settlement: Winners and Losers

Medtronic  has finally settled with Edwards Lifesciences  regarding allegations of infringing on Edwards' patents by marketing and selling the CoreValve transcatheters. The settlement worked out to a $750 million one-time payment and royalty payments on CoreValve sales from now until 2022.

Obviously, Edwards shareholders have got to be pleased that management's strong defense of its patents has paid off so handsomely, and the additional revenues from that victory are welcome news for any company. 

Medtronic's shareholders also may have good reason to be pleased, as there will be no more lawsuits from now until 2022 -- and the company had suffered a series of legal setbacks in this patent dispute.

In this video, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts David Williamson and Michael Douglass discuss the settlement's winners and losers.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

The article $1.1 Billion Settlement: Winners and Losers originally appeared on Fool.com.

David Williamson and Michael Douglass have no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story